Organ-derived peptide research
Pineal, retinal, prostate and kidney preparations: what was tested, what the studies found, and how the extracts relate to synthetic peptides.
Pineamin ↗
Pineal-gland polypeptide research now extends beyond menopausal symptoms into reproductive measures. These are separate clinical questions, with different comparators and endpoints.
Findings
The 94-woman placebo comparison reports sleep-related improvements. Smaller reproductive studies examine semen parameters, follicular biology and IVF pregnancies.
Semen quality and pregnancy findings do not establish live-birth benefit. Epithalamin aging reports remain evidence for that extract, not Pineamin.
Efficacy of non-hormonal therapy in women with climacteric syndrome ↗
Pineamin and ejaculate quality and symptoms associated with male aging ↗
Pineamin in combined therapy for diminished ovarian reserve ↗
Retinalamin ↗
The retinal extract has randomized glaucoma reports and a more recent prospective cohort. Structural measures, visual-field tests and visual acuity should be read separately.
Findings
The 2019 report describes favorable visual-field trends. In the 24-month study, several end-of-study comparisons were not significant. A rabbit photochemical-injury experiment found no protective effect.
A retinal research association does not make Normophthal or another short peptide equivalent to Retinalamin.
Neuroprotective therapy in advanced primary open-angle glaucoma ↗
Prostateks ↗
A prostate-extract preparation with its own postoperative clinical report. It belongs beside Prostatilen and Prostamax in the research collection, with product identity preserved.
Findings
The 127-patient comparison reports greater improvement in urinary symptoms and flow with adjunctive Prostateks after surgery.
Both groups received tamsulosin and underwent surgery. This does not establish a standalone effect or equivalence to another prostate product.
Prostate extract after transurethral resection for benign prostatic hyperplasia ↗
Nephropept ↗
A kidney-derived complex represented in organotypic culture research and a clinical-development listing for diabetic chronic kidney disease.
Findings
The culture paper names Nephropept directly. The Phase II registry reproduction specifies a planned 210-person placebo-controlled study, but supplies no clinical results.
Listed dates do not confirm completion or enrollment. Pielotax and synthetic EDL are separate preparations; their findings cannot substitute for Nephropept outcomes.
Combined effect of polypeptide complexes on organotypic rat tissue cultures ↗
From extracts to defined sequences
Three relationships need separate documentation: a sequence proposed from an extract’s amino-acid composition, a sequence detected by analytical methods, and a synthetic peptide studied independently. None, by itself, establishes that the mixture and the sequence have the same clinical effects.
| Research branch | Relationship | Sources |
|---|---|---|
| Pineal | AEDG detection in pineal complex is documented separately from Pineamin clinical studies. Pinealon is EDR, a different sequence associated with brain research. | Pineal composition · Pinealon |
| Brain, vessels, cartilage, bronchi and pancreas | The multi-organ analytical report supports particular sequence-to-complex links. It does not establish clinical interchangeability of marketed products. | 2020 analytical paper |
| Kidney | EDL renal-injury experiments concern a synthetic sequence. These experiments do not identify EDL as a constituent of Nephropept. | EDL rat experiments · Pielotax report |
| Prostate | Prostateks, Prostatilen and synthetic Prostamax have different preparation identities. Their source records should remain separate. | Prostatilen · Prostamax |
Documents that would resolve the remaining questions
The Nephropept clinical-study report and original regulatory record are priorities. Other recovery targets include the larger Pineamin development program, Retinalamin macular-degeneration protocols, and primary composition data connecting newer organ extracts to proposed short sequences. These leads are not counted as positive studies.